We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients.
- Authors
Capria, Saveria; Trisolini, Silvia Maria; Minotti, Clara; Stefanizzi, Caterina; Cardarelli, Luisa; Canichella, Martina; Cartoni, Claudio; Diverio, Daniela; De Propris, Maria Stefania; Mancini, Marco; Micozzi, Alessandra; Foà, Robin; Meloni, Giovanna
- Abstract
Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation. We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main end points were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant. Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.
- Subjects
ACUTE myeloid leukemia treatment; ACUTE leukemia; DISEASE relapse; TRANSPLANTATION of organs, tissues, etc.; DRUG therapy; STEM cell transplantation; PATIENTS
- Publication
Mediterranean Journal of Hematology & Infectious Diseases, 2012, Vol 4, Issue 1, p1
- ISSN
2035-3006
- Publication type
Article
- DOI
10.4084/MJHID.2012.072